Egis Pharmaceuticals PLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Egis Pharmaceuticals PLC
Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
Pfizer won EU antitrust approval for its plan to buy Hospira after promising to divest certain assets including its own biosimilar version of tumor necrosis factor inhibitor infliximab, to allay competition concerns. Still open are questions about possible buyers and what this means for competitors.
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
- Generic Drugs
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.